NMCC Clinical Trials: Recruiting

CLINICAL TRIALS MENU

The listing below of clinical trials in use by New Mexico Cancer Center is primarily intended for medical and radiation oncologists, nurses and clinical trial coordinators. If you are a patient, we encourage you to discuss with your oncologist whether there are any clinical trials that might be of benefit to you. Unless otherwise noted, the information below, including Trial Status, Date Opened and Date Updated, is obtained from ClinicalTrials.gov. Complete detailed information including eligibility criteria for each trial is available by clicking the ClinicalTrials.gov link provided in that trial's Description Box.

Category Trial ID Org Description
Official Title / (Optional) Comment / ClinicalTrials.gov link
Trial Status Opened


Updated
Breast Adjuvant Alliance A011502 NMCCA

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial


CinicalTrials.govDetails and eligibility criteria
Recruiting 4 May 2017


29 Mar 2018
Breast Adjuvant Alliance A221505 NMCCA

Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction


Radiation


CinicalTrials.govDetails and eligibility criteria
Recruiting 30 Jan 2018


6 Sep 2018
Breast Adjuvant Alliance Foundation Trials AFT-05, ABCSG 42, BIG 14-0 (PALLAS) NMCCA

PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer


CinicalTrials.govDetails and eligibility criteria
Recruiting 31 Jul 2015


3 Sep 2018
Breast Adjuvant ECOG-ACRIN EA1131 NMCCA

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy


CinicalTrials.govDetails and eligibility criteria
Recruiting 29 Jul 2016


29 Mar 2018
Breast Adjuvant NSABP B51/RTOG 1304 NMCCA

A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy


Radiation


CinicalTrials.govDetails and eligibility criteria
Recruiting 7 Jun 2013


16 May 2017
Breast Adjuvant SWOG S1207 NMCCA

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer


CinicalTrials.govDetails and eligibility criteria
Recruiting 28 Aug 2012


31 Aug 2018
Breast Adjuvant SWOG S1418/BR006 NMCCA

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy


CinicalTrials.govDetails and eligibility criteria
Recruiting 4 Nov 2016


16 Nov 2018
Breast Advanced Alliance Foundation Trials AFT-38 NMCCA

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer


Metastatic, First Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 28 Oct 2016


19 Jun 2018
Breast Advanced ECOG E2112 NMCCA

A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer


Metastatic, Second-Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 16 Apr 2014


23 Oct 2018
Breast Advanced Macrogenics, Inc. CP-MGAH22-04 NMCCA

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment


Metastatic, Second-Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 9 Jul 2015


18 Oct 2018
Breast Advanced NRG-BR002 NMCCA

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer


Metastatic, First Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 18 Feb 2015


5 Nov 2018
Breast Advanced ODO-TE-B301 NMCCA

Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane


Metastatic, First-Line & Second-Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 31 Oct 2017


2 Nov 2018
Breast Advanced SWOG S1416 NMCCA

Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer


Metastatic, First-Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 5 Nov 2015


16 Nov 2018
Breast Neoadjuvant Alliance A011106 NMCCA

Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women: A Phase III Study


ER+, HER2-. Enrolling in ARM 1, Anastrozole only.


CinicalTrials.govDetails and eligibility criteria
Recruiting 1 Oct 2013


6 Sep 2018
GI Colorectal Adjuvant SWOG S0820 NMCCA

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)


CinicalTrials.govDetails and eligibility criteria
Recruiting 9 May 2011


31 Aug 2018
GI Colorectal Advanced Canstem 303C NMCCA

A Phase 3 Study of BBI-608 in Combination With 5-Fluorouracil, Leucovorin, Irinotecan (FOLFIRI) in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CRC).


Metastatic, Second-Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 27 Apr 2016


15 Oct 2018
GI Colorectal Advanced SWOG S1613 NMCCA

S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification


Metastatic, Second-Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 7 Dec 2017


31 Aug 2018
GI Non-Specific Astellas/8951-CL-0302 PCR

A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma


CinicalTrials.govDetails and eligibility criteria
Recruiting 31 Aug 2018


16 Nov 2018
GI Pancreatic Advanced Canstem 111P NMCCA

A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma


Metastatic, First-Line


CinicalTrials.govDetails and eligibility criteria
Recruiting 15 Dec 2016


5 Nov 2018
GU Non-Specific Immu-132-06 PCR

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy


CinicalTrials.govDetails and eligibility criteria
Recruiting 6 Jun 2018


9 Nov 2018
GU Prostate Adjuvant Advantagene PrTK03 NMCCA

A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer


CinicalTrials.govDetails and eligibility criteria
Recruiting 20 Sep 2011


14 Nov 2018
GU Prostate Adjuvant NRG-GU005 NMCCA

Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer


CinicalTrials.govDetails and eligibility criteria
Recruiting 11 Dec 2017


6 Nov 2018
GU Prostate Advanced Alliance AFT-19 NMCCA

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer


Post-Prostatectomy


CinicalTrials.govDetails and eligibility criteria
Recruiting 4 Jan 2017


5 Sep 2018
GU Prostate Metastatic VISION 177Lu-PSMA-617 / PCR Trial PCR

VISION: An International, Prospective, Open Label, Multicenter, Randomized Phase 3 Study of 177Lu-PSMA-617 in the Treatment of Patients With Progressive PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC)


CinicalTrials.govDetails and eligibility criteria
Recruiting 30 Apr 2018


15 Nov 2018
Head And Neck Adjuvant ECOG-ACRIN EA3132 NMCCA

Phase II Randomized Trial of Adjuvant Radiotherapy with or Without Cisplatin for p53 Mutated, Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN)


CinicalTrials.govDetails and eligibility criteria
Recruiting 12 Apr 2016


2 Aug 2018
Hematology – See: Blood
Ill Defined SWOG S1609 NMCCA

SWOG S1609: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors


CinicalTrials.govDetails and eligibility criteria
Recruiting 15 Jul 2016


16 Nov 2018
Leukemia – SEE: blood
Lung NSCLC Adjuvant Alliance A081105 NMCCA

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)


CinicalTrials.govDetails and eligibility criteria
Recruiting 17 Jul 2014


16 Nov 2018
Lung NSCLC Adjuvant Alliance A151216 NMCCA

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)


CinicalTrials.govDetails and eligibility criteria
Recruiting 18 Jul 2014


16 Nov 2018
Lung NSCLC Adjuvant ECOG-ACRIN E4512 NMCCA

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the anaplastic Lymphoma Kinase (ALK) Fusion Protein


CinicalTrials.govDetails and eligibility criteria
Recruiting 28 Jul 2014


11 Dec 2017
Lung NSCLC Advanced BMS CA209568 NMCCA

A Study of Nivolumab in Combination with Ipilimumab (part 1); and Nivolumab plus Ipilimumab in Combination with Chemotherapy vs. Chemotherapy alone (part 2) as First Line Therapy in stage IV Non-Small Cell Lung Cancer (NSCLC)


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 9 May 2017


29 Mar 2018
Lung NSCLC Advanced SWOG S1403 NMCCA

A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)


CinicalTrials.govDetails and eligibility criteria
Recruiting 8 May 2015


10 Apr 2018
Lung Other SWOG S1400 NMCCA

Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 13 Feb 2017


Lung SCLC Advanced SWOG S1400G NMCCA

A Phase II Study of Talazoparib (BMN 673) in Patients with Homologous Recombination Repair Deficiency Positive Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)


CinicalTrials.govDetails and eligibility criteria
Recruiting 19 Dec 2017


31 Aug 2018
Lung SCLC Advanced SWOG S1400I NMCCA

A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-Map Sub-Study)


CinicalTrials.govDetails and eligibility criteria
Recruiting 30 May 2016


31 Aug 2018
Molecular Genetics INST 96144 City of Hope NMCCA

Molecular Genetics Studies of Cancer Patients and Their Relatives


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 9 Dec 2014


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-A NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-B NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-C1 NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-C2 NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol C2: Crizotinib in Patients with Tumors with MET Exon 14 Deletion


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-E NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-J NMCCA

Trastuzumab and Pertuzumab (HP) in Patients with Non-Breast, Non-Gastric/GEJ Cancers with HER2 Amplification


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 11 Mar 2017


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-L NMCCA

Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with mTOR Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 11 Mar 2017


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-M NMCCA

Phase II Study of MLN0128 (TAK-228) in Patients with Tumors with TSC1 or TSC2 Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 11 Mar 2017


20 Nov 2018
Mutation Based ECOG-ACRIN EAY131-S2 NMCCA

Phase II Study of Trametinib in Patients with Tumors with GNAQ or GNA11 mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-T NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol T: GDC-0449 (vismodegib) in Patients with Tumors (except basal cell skin carcinoma) with Smoothened (SMO) or Patched 1 (PTCH1) Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-U NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-V NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-W NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol W: Phase II Study of AZD4547 in Patients with Tumors with Aberrations in the FGFR Pathway


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-X NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol X: Phase II Study of Dasatinib in Patients with Tumors with DDR2 Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-Y NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Y: AZD5363 in Patients with Tumors with AKT Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-Z1A NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1A: Binimetinib in Patients with Tumors (Other Than Melanoma) with NRAS Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-Z1B NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CCND1, 2, 3 Amplification and Rb Protein Expression by IHC


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-Z1C NMCCA

Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 11 Mar 2017


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-Z1D NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol Z1D: Nivolumab in Patients with Tumors with Mismatch Repair Deficiency (Excluding Colorectal Cancer)


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-Z1E NMCCA

LOXO-101 in Patients with Tumors with NTRK Fusions


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 11 Mar 2017


29 Mar 2018
Mutation Based ECOG-ACRIN EAY131-Z1I NMCCA

Phase II Study of AZD1775 in Patients with Tumors Containing BRCA1 and BRCA2 Mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 11 Mar 2017


29 Mar 2018
Pancreatic – SEE: GI Pancreatic
Prostate (all stages) – SEE: GU Prostate
Skin Melanoma Advanced ECOG-ACRIN EA6134 NMCCA

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 26 Apr 2017


17 Nov 2018
Solid Tumors Other ECOG-ACRIN EAY131-F NMCCA

Molecular Analysis for Therapy Choice(MATCH)Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Solid Tumors Other ECOG-ACRIN EAY131-G NMCCA

Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Solid Tumors Other ECOG-ACRIN EAY131-H NMCCA

Molecular Analysis for Therapy Choice (MATCH) Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
Solid Tumors Other ECOG-ACRIN EAY131-R NMCCA

Molecular Analysis for Therapy Choice (MATCH)Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations


Unable to find this clinical trial listed on ClinicalTrials.gov
Recruiting 5 Nov 2016


29 Mar 2018
TRIAL STATS: Recruiting Only, Total = 61

Your Strongest Ally to Conquer Cancer

Pin It on Pinterest